Company intelligence / Profile preview

JOURNAVX

Bothell, Washington, United States

Ownership: Private
Development stage: Other

Overview

JournavX is a private biotechnology company based in Bothell, Washington, focused on developing next-generation cancer therapeutics. The company was founded by Dr. Clay Siegall, a prominent figure in the biopharmaceutical industry and the former CEO of Seagen. JournavX primarily operates in stealth mode, leveraging proprietary technology to advance a pipeline of antibody-drug conjugates (ADCs) and other targeted biologics. The firm aims to address significant unmet needs in oncology by combining innovative targeting mechanisms with potent therapeutic payloads. With a leadership team experienced in bringing successful cancer drugs to market, JournavX is positioned as a key emerging player in the Seattle-area biotech hub.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on JOURNAVX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JOURNAVX.

Explore the full profile